Patents by Inventor Shimiao Wang

Shimiao Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted nicotinamide derivatives as kinase inhibitors
    Patent number: 9567324
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 14, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Shimiao Wang, Thomas C. Malone, Julie Wurster, Jie Shen, Michael Robinson
  • SOMATOSTATIN MODULATORS AND USES THEREOF
    Publication number: 20170001966
    Abstract: Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.
    Type: Application
    Filed: June 17, 2016
    Publication date: January 5, 2017
    Inventors: Jian ZHAO, Yunfei ZHU, Shimiao WANG, Sangdon HAN, Sun Hee KIM
  • Indole-3-carboxamides as kinase inhibitors
    Patent number: 9403803
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20160194311
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 14, 2016
    Publication date: July 7, 2016
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • Pyridyl benzothiophenes as kinase inhibitors
    Patent number: 9371314
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
    Patent number: 9359336
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 7, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Indole-1-carboxamides as kinase inhibitors
    Patent number: 9353093
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: May 31, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • PYRIDYL BENZOTHIOPHENES AS KINASE INHIBITORS
    Publication number: 20160102080
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Indole-3-Carboxamides as Kinase Inhibitors
    Publication number: 20160102077
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Heterocycle-substituted Pyridyl Benzothiophenes as Kinase Inhibitors
    Publication number: 20160102081
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Indole-1-Carboxamides as Kinase Inhibitors
    Publication number: 20160096828
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 7, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Substituted dialkyl(oxido)-lambda4-sulfanylidene nicotinamide derivatives as kinase inhibitors
    Patent number: 9266869
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 23, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • Kinase inhibitors
    Patent number: 9233968
    Abstract: Described herein are compounds which in some embodiments are capable of modulating, regulating, and/or inhibiting tyrosine kinase signal transduction, as well as methods and compositions related to the compounds.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: January 12, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Thomas C. Malone
  • SUBSTITUTED DIALKYL(OXIDO)-LAMBDA4-SULFANYLIDENE NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150166521
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • SUBSTITUTED NICOTINAMIDE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20150166518
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: December 10, 2014
    Publication date: June 18, 2015
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • Sulfoximines as kinase inhibitors
    Patent number: 8558002
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: October 15, 2013
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Shimiao Wang, Julie A. Wurster
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 8455535
    Abstract: The present invention provides a compound represented by the formula: wherein ring systems A and B, and the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. The compounds of the present invention may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, such as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: June 4, 2013
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • SULFOXIMINES AS KINASE INHIBITORS
    Publication number: 20120196902
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: October 20, 2011
    Publication date: August 2, 2012
    Inventors: Sougato Boral, Shimiao Wang, JULIE A. WURSTER
  • Heteroaryl Dihydroindolones as Kinase Inhibitors
    Publication number: 20110257238
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Application
    Filed: June 1, 2011
    Publication date: October 20, 2011
    Applicant: ALLERGAN, INC.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone
  • Heteroaryl dihydroindolones as kinase inhibitors
    Patent number: 7977351
    Abstract: The present invention provides a compound represented by the formula: wherein the variables R1, b, R6, Y, Z, X, R and a are defined in the specification. Said compound may be used in a method for treating diseases related to unregulated tyrosine kinase signal transduction, wherein said disease is selected from the group consisting of cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, and metabolic diseases.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: July 12, 2011
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Xialing Guo, Shimiao Wang, Julie A. Wurster, Thomas C. Malone